Saturday 7 November 2026 Export KALA’s income statement to Excel — free account

KALA BIO, Inc.

KALA Healthcare Biotechnology

KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million.

EPS: +99.9%
Free cash flow: +80.2%

Quarter to June 2026, against a year earlier

0.16 0.01 +6.67%

Follow KALA

Alert me

Market cap: $3.0M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: 3/9
Altman Z: −11.18
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.60%

Capital & Financial Ratios $m

Size

Market Cap 2.95

Revenue ttm 5.75

Net income ttm (10.08)

Free cash flow ttm (19.86)

Net debt Q (7.23)

Valuation

P/E 0.00

Forward P/E (0.77)

Price / sales 0.52

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.33

Financial health

Current ratio Q 6.88

Debt / equity Q 0.00

Interest coverage Q (72.52)

Growth

Revenue growth Q −86.31%

Operating income growth Q +84.39%

EPS, this year +56.16%

EPS, next year A +88.09%

Revenue, next year A −57.09%

EPS, past 5 yrs —

EPS, next 5 yrs A +65.97%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.33%

10-year low 10-year high

P/B against its own 10 years 0.86%

10-year low 10-year high

EV/Sales against its own 10 years 56.36%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	51	51	8	7
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	53	53	9	11

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	10	—	—
Other	—	—	—	—
	8	17	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(13.79%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(41.25%)	(28.29%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY25 Estimate −91.00 Actual −85.50

−129.15 −112.57 −96.00 −79.42 −62.85

Q3 FY24 Beat +25.00

Q4 FY24 Beat +27.00

Q1 FY25 Beat +31.00

Q2 FY25 Beat +5.50

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY24	−121.50	−96.50	Beat by 25.00
Q4 FY24	−114.00	−87.00	Beat by 27.00
Q1 FY25	−101.50	−70.50	Beat by 31.00
Q2 FY25	−91.00	−85.50	Beat by 5.50

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.14)	(0.08)	—	—	—
’25	(70.50)	(85.50)	(53.50)	2.70	(165.50)
’24	(210.00)	(158.00)	(96.50)	(87.00)	(507.50)
’23	(349.50)	(218.00)	(170.50)	(159.00)	(867.50)
’22	(1.12k)	(950.00)	962.50	(398.50)	(1.47k)
’21	(1.22k)	(1.42k)	(1.07k)	(1.70k)	(5.47k)
’20	(1.35k)	(1.05k)	(1.25k)	(1.37k)	(4.97k)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	1	2	0	—	4
’21	3	3	3	2	11
’20	1	1	2	2	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(9)	(8)	(11)	(5)	(32)
’24	(11)	(9)	(5)	(5)	(29)
’23	(10)	(8)	(3)	(8)	(28)
’22	(24)	(25)	(16)	(14)	(79)
’21	(33)	(22)	(26)	(28)	(108)
’20	(20)	(19)	(26)	(26)	(91)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(9)	(8)	(11)	(5)	(32)
’24	(11)	(9)	(5)	(5)	(30)
’23	(10)	(8)	(3)	(8)	(28)
’22	(24)	(26)	(16)	(14)	(79)
’21	(33)	(22)	(26)	(28)	(109)
’20	(20)	(20)	(26)	(26)	(93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	6	6	11	4	—	—	—	6		(13.8%)	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	66.94	50.13	63.55	34.22	—	—	—	0.00		+34.2 pt	Powerpack KALA BIO, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(33)	(42)	(67)	(94)	(104)	(143)	(45)	(42)	(39)	(27)	(10)		(2.3%)
	EBT margin, %	0.00	0.00	0.00	(1,553.29)	(1,639.85)	(1,268.73)	(1,151.64)	0.00	0.00	0.00	0.00		0.0 pt
	Net income	(33)	(42)	(67)	(94)	(104)	(143)	(45)	(42)	(39)	(27)	(10)		(2.3%)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	443.36	302.95	427.38	128.03	0.00	0.00	0.00	0.00		n/m
	Earnings	(70,209.57)	(9,277.14)	(6,225.00)	(6,900.00)	(4,975.00)	(5,475.00)	(1,474.00)	(867.50)	(507.50)	(165.50)	(51.02)		(48.9%)
	Cash flow	(54,696.00)	(7,412.61)	(5,058.04)	(6,767.88)	(4,318.76)	(4,115.40)	(2,595.66)	(574.63)	(387.11)	(196.26)	(1.06)		(46.5%)
	Capex	(306.00)	(104.35)	(147.48)	(97.45)	(92.48)	(30.19)	(6.55)	(11.58)	(2.74)	(0.09)	0.00		(59.4%)
	Free cash flow	(55,002.00)	(7,516.96)	(5,205.51)	(6,865.33)	(4,411.24)	(4,145.59)	(2,602.20)	(586.21)	(389.86)	(196.36)	(1.06)		(46.5%)
	Book value	61,258.00	19,495.43	9,811.03	2,167.30	4,761.67	638.94	624.14	154.40	162.48	42.92	0.48		(55.4%)
	Shares, m	0	0	0	0	0	0	0	0	0	0	8		+90.2%
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	—	—	—	0.00		0.0
	P/S	—	—	—	20.81	55.95	7.08	8.45	—	—	—	0.52		23.1
	P/B	—	—	—	4.26	3.56	4.73	2.56	—	—	—	0.33		3.8
	EV/Sales	—	—	—	18.68	43.41	7.19	5.21	—	—	—	8.04		18.6
	EV/FCF	—	—	—	(1.21)	(2.98)	(0.74)	(0.38)	—	—	—	(2.31)		(1.3)
Cash, $m
Cash, $m	Operating cash flow	(27)	(34)	(54)	(93)	(91)	(108)	(79)	(28)	(29)	(32)	(20)		+1.8%
	Capex	0	0	(2)	(1)	(2)	(1)	0	(1)	0	0	0		(22.7%)
	Free cash flow	(28)	(35)	(56)	(94)	(93)	(109)	(79)	(28)	(30)	(32)	(20)		+1.7%
Balance, $m
Balance, $m	Working capital	40	100	160	81	149	87	60	45	36	7	9		(17.6%)
	Net debt	(36)	(96)	(100)	(13)	(80)	1	(19)	(13)	(16)	(8)	(7)		(15.9%)
	Shareholders’ equity	31	90	105	30	100	17	19	8	12	7	9		(15.1%)
Returns, %
Returns, %	ROA	(143.18)	(51.83)	(39.55)	(50.28)	(55.50)	(79.00)	(39.62)	(59.12)	(69.12)	(83.05)	(43.23)		+60.1 pt
	ROIC	0.00	0.00	(848.20)	(329.12)	(297.33)	(449.62)	(13,403.22)	0.00	0.00	0.00	(722.69)		0.0 pt
	ROE	(3,460.30)	(4,403.86)	(68.57)	(140.12)	(160.89)	(244.19)	(250.56)	(318.75)	(388.29)	(279.19)	(345.32)		+3,181.1 pt
People
People	Employees	25	37	130	136	188	192	34	43	38	6	—		(14.7%)
	Revenue/emp, $m	0.00	0.00	0.00	0.04	0.03	0.06	0.11	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Sep 2022 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SXTP 60 Degrees Pharmaceuticals Inc.	$3.2M	— (loss-making)	— (loss-making)	−32.48% (below 0%: shrinking)	n/m	−54.33% (below 0%: shrinking)	27.32%	(1,092.40%)	Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR	$3.1M	— (loss-making)	— (loss-making)	−85.95% (below 0%: shrinking)	n/m	−2.73% (below 0%: shrinking)	(2.67%)	0.00%	Compare
ERNA Ernexa Therapeutics Inc.	$3.0M	— (loss-making)	— (loss-making)	−94.12% (below 0%: shrinking)	n/m	−64.10% (below 0%: shrinking)	100.00%	0.00%	Compare
MBIO Mustang Bio, Inc.	$3.0M	— (loss-making)	—	—	n/m	+27.78% (above 0%: growing)	0.00%	0.00%	Compare
CMND Clearmind Medicine Inc.	$3.0M	— (loss-making)	—	—	n/m	−77.94% (below 0%: shrinking)	0.00%	0.00%	Compare
KALA KALA BIO, Inc.	$3.0M	— (loss-making)	— (loss-making)	−86.31% (below 0%: shrinking)	n/m	+80.19% (above 0%: growing)	0.00%	0.00%
BCAB BioAtla, Inc.	$2.9M	— (loss-making)	— (loss-making)	+4,233.33% (above 0%: growing)	n/m	+97.03% (above 0%: growing)	100.00%	3.49%	Compare
JUNS Jupiter Neurosciences, Inc.	$2.8M	— (loss-making)	—	—	n/m	−177.06% (below 0%: shrinking)	87.19%	(11,334.30%)	Compare
AFMDQ Affimed N.V.	$2.8M	— (loss-making)	— (loss-making)	−92.02% (below 0%: shrinking)	n/m	+46.95% (above 0%: growing)	100.00%	(9,216.90%)	Compare
Median of peers	$3.0M	—	—	−85.95%	—	−28.53%	57.26%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 September 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	906.64k	(1.01m)	0.56
2024	1.49m	1.26m	6.94
2023	8.34m	3.75m	2.06

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

KALA BIO, Inc. (KALA) Latest News

29 Sep

Impact 4 · 7:30 AM · TMX Newsfile

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Impact 3 · 8:00 AM · GlobeNewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresZacks

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

24 Sep

Impact 3 · 7:30 AM · GlobeNewswire

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

3 Sep

Impact 3 · 9:47 AM · InvestorsHub

Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests

Impact 3 · 8:30 AM

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Impact 3 · 8:00 AM · GlobeNewswire

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

1 Sep

Impact 3 · 11:05 AM · InvestorsHub

Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership

Impact 3 · 7:45 AM

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

7 May

Impact 3 · 9:00 AM

KALA BIO Announces Reverse Stock Split

21 Apr

Impact 5 · 7:00 AM

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

1 Apr

Impact 3 · 6:45 AM · GlobeNewswire

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

30 Mar

Impact 4 · 8:45 AM · GlobeNewswire

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

18 Mar

Impact 4 · 9:00 AM · GlobeNewswire

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

Impact 3 · 8:15 AM · TMX Newsfile

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

11 Mar

Impact 4 · 6:30 AM · GlobeNewswire

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

Impact 3 · 11:18 AM · TMX Newsfile

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

4 Mar

Impact 4 · 6:30 AM · GlobeNewswire

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

5 Jan

Impact 3 · 4:10 PM · GlobeNewswire

KALA BIO Settles Approximately $10.6 million of Debt

5 Dec

Impact 3 · 2:36 PM · GlobeNewswireMT NewswiresMT NewswiresMT NewswiresInsider MonkeyMT NewswiresMT NewswiresMT Newswires

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

4 Dec

Impact 3 · 10:45 AM · GlobeNewswire

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

1 Dec

Impact 3 · 1:32 PM · MT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires

Top Midday Gainers

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

Impact 3 · 7:00 AM · GlobeNewswire

KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

19 Nov

Impact 3 · 6:11 PM · Associated Press Finance

KALA BIO: Q3 Earnings Snapshot

8 Oct

Impact 4 · 11:18 AM · Zacks

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

30 Sep

Impact 3 · 2:22 PM · MT Newswires

Top Midday Decliners

5 Sep

Impact 3 · 6:20 AM · Simply Wall St.

KALA BIO, Inc.'s (NASDAQ:KALA) market cap surged US$28m last week, retail investors who have a lot riding on the company were rewarded

2 Sep

Impact 4 · 8:00 AM · GlobeNewswireGlobeNewswireGlobeNewswireMT NewswiresNewsfileGlobeNewswireGlobeNewswireGlobeNewswire

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

13 Aug

Impact 4 · 9:55 AM

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

KALA BIO, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

KALA BIO, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 24 September 2026

Chief executive’s pay

KALA BIO, Inc. (KALA) Latest News

29 Sep

24 Sep

3 Sep

1 Sep

7 May

21 Apr

1 Apr

30 Mar

18 Mar

11 Mar

4 Mar

5 Jan

5 Dec

4 Dec

1 Dec

19 Nov

8 Oct

30 Sep

5 Sep

2 Sep

13 Aug

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

KALA BIO, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 24 September 2026

Chief executive’s pay

KALA BIO, Inc. (KALA) Latest News

29 Sep

24 Sep

3 Sep

1 Sep

7 May

21 Apr

1 Apr

30 Mar

18 Mar

11 Mar

4 Mar

5 Jan

5 Dec

4 Dec

1 Dec

19 Nov

8 Oct

30 Sep

5 Sep

2 Sep

13 Aug

Stockrow Weekly